Clinical Evidence

Antioxidant properties of curcumin and its impact on arteriovenous fistula maturation in end-stage kidney disease patient with diabetes mellitus type 2
Int J Res Pharm Sci.2020; 11(4): 7624-7629. DOI:
Globally, the most common cause of the end-stage kidney disease is diabetes mellitus. Although kidney transplantation is the first-line treatment option for end-stage kidney disease, most preferred is hemodialysis due to several reasons. In diabetes mellitus, vascular flow alteration plays a major role in arteriovenous fistula (AVF) maturation failure.
A phytochemical component ‘curcumin’ has proven antioxidant, antiproliferative and antitumorigenic which might prevent AVF maturation failure.

To assess the effect of curcumin and acetylsalicylic acid on total antioxidant capacity (TAC) in end-stage kidney disease patient with diabetes mellitus type 2 (ESRD) patients.


This is a single-blinded, randomized controlled trial in 67 end-stage kidney disease patients with diabetes mellitus type 2 patients. The subjects were randomly assigned into curcumin group (2000 mg/day), acetylsalicylic acid group (80mg/day), and placebo, supplemented for 4 weeks. All the subjects were followed-up weekly for their drug compliance, antioxidant assessment was done in 4th and 8th week follow-up. Arteriovenous fistula was considered as mature according to the national kidney foundation kidney disease outcomes quality initiative (NKF-KDOQI) guidelines.

  • Curcumin at a dose of 2000 mg/day increased the total antioxidant capacity after 4th [794.2 (457.4 ± 1473.7) µM] and 8th weeks [820.5 (380.7± 1643.7) µM] following arteriovenous fistula surgery

Curcumin C3 Complex® at 2000 mg/day helped in arteriovenous fistula maturation among end-stage renal disease patients with type 2 diabetes by increasing antioxidant capacity.